Just four months after signing a licensing deal for one of Kiadis Pharma NV's modified natural killer (NK) cell therapies, Sanofi has offered €308m to acquire the Dutch biotech, a bid that has the unanimous support of the latter's board.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?